What Would You Change About the EOM?

EP: 1.No Successor to OCM Would Disappoint

EP: 2.CMMI Open to Feedback, but EOM Out of the Blue

EP: 3.Some Practices That Did Not Do OCM Are Applying

EP: 4.Seven Tumor Types: Pros and Cons

EP: 5.A Model That Is Built to “Win”

EP: 6.Addressing Health Equity and Social Needs

EP: 7.Is Five Years Long Enough?

EP: 8.Changes to MEOS and Barriers to Entry

EP: 9.Small Practices and Dual Risk: Considerations and Approaches

EP: 10.Does Pooling Make Sense?

Now Viewing

EP: 11.What Would You Change About the EOM?

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, invites the panelists to discuss one element of the Enhancing Oncology Model (EOM) they would change, and why. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and COA president, called for CMS to include a factor to recognize the effects of COVID long haulers on total cost of care. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, returned to the MEOS payments and suggested either making them higher or creating an add-on payment to reward data collection. And Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, agreed with higher MEOS payments to attract new participants but also called for a system that doesn't punish practices that prescribe newly approved, high cost drugs if they are right for the patient.